Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Cell Harvesting Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top Cell Harvesting Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
4.80 Billion
2026 Forecast (US$)
5.32 Billion
2032 Forecast (US$)
9.93 Billion
CAGR (2025-2032)
10.80%

Summary

The cell harvesting market is entering a strong expansion phase, driven by regenerative medicine, cell and gene therapies, and higher bioprocess efficiency demands. Leading Cell Harvesting market companies are consolidating share through automation, closed-system workflows, and single-use technologies. Global market value is projected to rise from US$ 4.80 Billion in 2025 to US$ 9.93 Billion by 2032, reflecting a 10.80% CAGR.

2025 Revenue of Top Cell Harvesting Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Cell Harvesting market companies are based on a composite scoring model combining quantitative and qualitative factors. Core criteria include 2025 cell harvesting revenue, 3-year growth trajectory, and share of global bioprocess equipment sales. We also assess competitive wins in biopharma and CDMO projects, installed base of harvesters and consumables, and breadth of product portfolio across automated systems, kits, and single-use components. Technology differentiation weighs advances in closed systems, sterility assurance, process analytics, and integration with upstream and downstream workflows. Service coverage considers global field support, validation expertise, and ability to manage long-term maintenance, calibration, and lifecycle management contracts. Scores are normalized to ensure comparability between diversified life-science conglomerates and specialized pure plays, and final ranking reflects the weighted average of all pillars.

Top 10 Companies in Cell Harvesting

1
Thermo Fisher Scientific Inc.
North America, Europe, Asia Pacific
Waltham, USA
Automated cell harvesters, single-use centrifugation systems, closed sterile transfer technologies.
Leading integrated provider of cell processing and harvesting solutions for biopharma and cell therapy.
Biopharma manufacturers, CDMOs, cell and gene therapy developers
US$ 820.00 Million
Expanded cell therapy workflow portfolio, acquisitions in single-use bioprocessing, digital integration of harvesting data.
2
Beckman Coulter Life Sciences
North America, Europe, Japan, China
Indianapolis, USA
High-speed centrifuges, automated harvest workflows, lab automation for cell processing.
Top-tier provider of centrifugation and automation platforms for cell harvesting and clarification.
Biotech firms, vaccine manufacturers, core laboratories
US$ 610.00 Million
Launched next-generation centrifuge line, expanded GMP-compliant service centers, collaborations with major CDMOs.
3
Sartorius AG
Europe, North America, Asia Pacific
Göttingen, Germany
Single-use filtration and harvesting, integrated bioreactor-to-harvest solutions.
Major European bioprocess vendor with strong single-use and cell harvesting portfolios.
Biopharma, biosimilar manufacturers, CDMOs
US$ 540.00 Million
Invested in EU manufacturing capacity, expanded digital twins for bioprocess optimization, targeted cell therapy alliances.
4
Merck KGaA (MilliporeSigma)
Europe, North America, Asia
Darmstadt, Germany
Clarification filters, depth filtration systems, harvest-ready disposable assemblies.
Diversified life-science supplier with strong position in downstream and harvest operations.
Large biopharma, vaccine producers, diagnostics manufacturers
US$ 485.00 Million
Broadened single-use harvest kits, expanded collaboration with leading CMOs, investment in low-shear technologies.
5
GE HealthCare (formerly Cytiva business overlaps)
North America, Europe, China
Chicago, USA
Centrifuge-based and filtration-based harvest platforms, integrated skids.
Key supplier of bioprocessing hardware, including cell harvest and clarification systems.
Biopharma, CDMOs, academic GMP facilities
US$ 430.00 Million
Developed high-throughput harvest platforms, partnered with cell therapy centers, enhanced process analytics.
6
Eppendorf SE
Europe, North America, Asia Pacific
Hamburg, Germany
Benchtop centrifuges, small bioprocess harvest modules, lab-scale automation.
Strong player in small-scale and pilot-scale cell harvesting and centrifugation.
Research institutes, biotech startups, clinical labs
US$ 260.00 Million
Introduced energy-efficient centrifuges, targeted cell therapy labs, expanded aftermarket service packages.
7
Terumo Blood and Cell Technologies
North America, Europe, Japan
Lakewood, USA
Apheresis systems, cell collection devices, clinical-scale harvest solutions.
Specialist in blood and cell processing with strong foothold in clinical harvesting.
Hospitals, blood centers, cell therapy clinics
US$ 240.00 Million
Expanded clinical cell therapy solutions, partnerships with transplant centers, regulatory clearances in new markets.
8
Miltenyi Biotec B.V. & Co. KG
Europe, North America, Asia
Bergisch Gladbach, Germany
Magnetic-activated cell sorting, closed harvest systems, cell therapy workflows.
Innovation-driven company focused on magnetic cell separation and harvesting for research and clinical use.
Academic centers, cell therapy developers, translational research institutes
US$ 210.00 Million
Launched automated GMP-compliant harvest platforms, strengthened OEM partnerships, broadened clinical applications.
9
Corning Incorporated (Life Sciences)
North America, Europe, Asia Pacific
Corning, USA
Cell culture systems, microcarriers, harvest-friendly vessels and accessories.
Key supplier of cell culture vessels with integrated harvest solutions.
Biotech companies, pharma R&D, academic laboratories
US$ 195.00 Million
Expanded high-density culture formats, integrated harvest ports, collaborations on closed-system workflows.
10
Bio-Techne Corporation
North America, Europe, Asia
Minneapolis, USA
Cell isolation reagents, small-scale automated harvesters, analytical tools.
Growing specialist in cell and gene therapy workflow tools including harvest and enrichment.
Cell and gene therapy firms, CROs, advanced therapy centers
US$ 160.00 Million
Invested in cell therapy platforms, expanded GMP reagent range, strategic alliances with therapy developers.

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Thermo Fisher Scientific Inc.

Global life-science leader providing end-to-end bioprocess and cell therapy solutions, including advanced automated cell harvesting platforms.

Key Financials: 2025 Cell Harvesting revenue US$ 820.00 Million; estimated segment growth 11.50% CAGR.
Flagship Products: CTS Rotea System, HyPerforma Single-Use Centrifuge, Harvestainer BioProcessing Systems
2025-2026 Actions: Acquired niche single-use vendor, expanded cell therapy workflow offering, integrated harvesting data into Chromeleon software.
Three-line SWOT: Broad portfolio across entire cell therapy workflow; High integration complexity for smaller customers; Opportunity—surging demand from commercial CAR-T manufacturers.
Notable Customers: Novartis, Lonza, Thermo Fisher Viral Vector Services
2

Beckman Coulter Life Sciences

Specialist in centrifugation and lab automation delivering reliable cell harvesting solutions from discovery to commercial manufacturing scale.

Key Financials: 2025 Cell Harvesting revenue US$ 610.00 Million; operating margin 18.20%.
Flagship Products: Allegra X-30 Series, Avanti J-26 XP, Biomek i-Series Automation
2025-2026 Actions: Released next-gen high-throughput centrifuges, expanded GMP service footprint, deepened collaborations with leading global CDMOs.
Three-line SWOT: Strong centrifugation heritage and installed base; Limited offering in single-use filtration; Opportunity—upgrading legacy centrifuges to connected, data-rich platforms.
Notable Customers: Catalent, FUJIFILM Diosynth Biotechnologies, GSK
3

Sartorius AG

European bioprocess powerhouse offering integrated single-use bioreactor, filtration, and cell harvesting platforms for scalable biologics production.

Key Financials: 2025 Cell Harvesting revenue US$ 540.00 Million; R&D spend 9.80% of bioprocess revenue.
Flagship Products: Sartoclear Dynamics, Sartoflow Smart, Biostat STR with harvest integration
2025-2026 Actions: Expanded EU manufacturing capacity, introduced digital twins for harvest optimization, formed alliances with cell therapy CDMOs.
Three-line SWOT: Leadership in single-use technologies; Exposure to European funding cycles; Opportunity—biosimilar expansion in Asia requiring robust harvest solutions.
Notable Customers: Samsung Biologics, Boehringer Ingelheim BioXcellence, WuXi Biologics
4

Merck KGaA (MilliporeSigma)

Diversified life-science company with strong downstream and clarification solutions supporting efficient, scalable cell harvesting workflows.

Key Financials: 2025 Cell Harvesting revenue US$ 485.00 Million; bioprocess solutions growth 10.30% year-on-year.
Flagship Products: Clarisolve Filters, Millistak+ Pod Filters, Mobius Single-Use Assemblies
2025-2026 Actions: Launched low-shear clarification filters, expanded Mobius single-use kits, partnered with top CDMOs on integrated harvest designs.
Three-line SWOT: Comprehensive filtration portfolio and process expertise; Complex product catalog; Opportunity—continuous bioprocessing adoption increasing demand for optimized harvest steps.
Notable Customers: Merck & Co., Lonza, Sanofi
5

GE HealthCare (formerly Cytiva business overlaps)

Major bioprocess technology supplier with harvest platforms integrated into upstream and downstream processing environments.

Key Financials: 2025 Cell Harvesting revenue US$ 430.00 Million; estimated bioprocess segment growth 10.10% CAGR.
Flagship Products: KUBio Bioprocessing Solutions, Xcellerex Harvest Skids, ReadyToProcess Filtration Systems
2025-2026 Actions: Developed high-throughput harvest skids, enhanced process analytics, expanded collaborations with cell therapy and vaccine manufacturers.
Three-line SWOT: Strong brand recognition and turnkey facilities; Portfolio complexity post corporate restructuring; Opportunity—greenfield biologics plants in emerging markets.
Notable Customers: Cipla Biotech, CSL Behring, regional CDMOs in China
6

Eppendorf SE

Trusted provider of centrifuges and small-scale bioprocess equipment serving research, pilot, and clinical cell harvesting needs.

Key Financials: 2025 Cell Harvesting revenue US$ 260.00 Million; EBITDA margin 17.40%.
Flagship Products: Centrifuge 5910 Ri, BioFlo 320 Bioprocess Control, benchtop harvest accessories
2025-2026 Actions: Launched energy-efficient centrifuges, developed cell therapy lab packages, expanded global service and preventive maintenance offerings.
Three-line SWOT: Strong brand in labs and small-scale systems; Limited presence in large commercial plants; Opportunity—scaling with fast-growing biotech startups.
Notable Customers: Academic GMP centers, emerging biotech firms, hospital-based research labs
7

Terumo Blood and Cell Technologies

Clinical-focused provider of blood and cell processing technologies supporting therapeutic cell collection and harvesting.

Key Financials: 2025 Cell Harvesting revenue US$ 240.00 Million; clinical solutions revenue growth 9.70%.
Flagship Products: Spectra Optia Apheresis System, Quantum Cell Expansion System, cell collection disposables
2025-2026 Actions: Expanded indications for apheresis platforms, secured new approvals in Asia, partnered with transplant and cell therapy centers.
Three-line SWOT: Strong presence in hospital-based cell collection; Less exposure to large-scale biomanufacturing; Opportunity—growing demand for autologous cell therapy harvesting.
Notable Customers: Major transplant centers, blood banks, cell therapy clinics
8

Miltenyi Biotec B.V. & Co. KG

Innovation-driven company specializing in magnetic cell separation and automated harvest solutions from research to clinical scale.

Key Financials: 2025 Cell Harvesting revenue US$ 210.00 Million; R&D intensity 13.60% of sales.
Flagship Products: CliniMACS Prodigy, MACSQuant Tyto, MACS MicroBeads and harvest kits
2025-2026 Actions: Rolled out GMP-compliant Prodigy upgrades, expanded clinical partnerships, strengthened OEM integration with major harvest workflows.
Three-line SWOT: Cutting-edge cell selection technologies; Higher price points versus generic options; Opportunity—expanding CAR-T and TIL therapy pipelines.
Notable Customers: Academic medical centers, cell therapy developers, specialty CROs
9

Corning Incorporated (Life Sciences)

Key supplier of advanced cell culture vessels and systems designed for efficient, gentle cell harvesting.

Key Financials: 2025 Cell Harvesting revenue US$ 195.00 Million; life sciences segment growth 8.90%.
Flagship Products: Corning CellSTACK, HYPERFlask Vessels, microcarrier-compatible harvest accessories
2025-2026 Actions: Expanded high-density culture offerings, integrated harvest ports into vessels, co-developed closed harvest workflows with major biopharma clients.
Three-line SWOT: Strong reputation in cell cultureware; Lower penetration in fully automated harvest systems; Opportunity—scale-up of adherent cell therapies.
Notable Customers: Biotech R&D groups, vaccine manufacturers, academic labs
10

Bio-Techne Corporation

Growing player providing reagents and instruments that enable precise small-scale cell harvesting and characterization.

Key Financials: 2025 Cell Harvesting revenue US$ 160.00 Million; cell and gene therapy segment growth 15.20%.
Flagship Products: CytoSoft Harvester Tools, automated small-scale harvesters, specialized cell isolation reagents
2025-2026 Actions: Invested in cell therapy workflow platforms, broadened GMP reagent catalog, formed alliances with therapy developers and CROs.
Three-line SWOT: Strong positioning in cell and gene therapy tools; Limited large-scale hardware; Opportunity—early engagement with next-generation therapy sponsors.
Notable Customers: Advanced therapy developers, contract research organizations, translational research institutes

SWOT Leaders

Thermo Fisher Scientific Inc.

SWOT Snapshot

SWOT
Strengths

Comprehensive end-to-end workflows, strong global footprint, and deep relationships with leading cell and gene therapy sponsors.

Weaknesses

Complex portfolio can challenge smaller customers and pricing is often higher than regional competitors.

Opportunities

Commercialization of new CAR-T and gene therapies requiring standardized, automated closed cell harvesting solutions.

Threats

Intensifying competition from agile specialists and potential regulatory shifts affecting integrated platform approvals.

Beckman Coulter Life Sciences

SWOT Snapshot

SWOT
Strengths

Large installed base of centrifuges, proven reliability, and strong automation capabilities supporting scalable cell harvesting.

Weaknesses

Less comprehensive offering in single-use and filtration-based harvesting compared with some European rivals.

Opportunities

Upgrade cycle for legacy centrifuges to connected, data-rich models in biopharma and CDMO facilities worldwide.

Threats

Price pressure from lower-cost manufacturers and risk of technology disruption from non-centrifugation harvest methods.

Sartorius AG

SWOT Snapshot

SWOT
Strengths

Leadership in single-use bioprocessing, integrated bioreactor-to-harvest solutions, and strong presence in biosimilar manufacturing.

Weaknesses

High exposure to European macroeconomic cycles and procurement budget fluctuations.

Opportunities

Rapid expansion of biologics and biosimilar capacity in Asia requiring scalable single-use harvest platforms.

Threats

Currency volatility, regulatory scrutiny on single-use waste, and increasing competition from Asian bioprocess vendors.

Cell Harvesting Market Regional Competitive Landscape

North America remains the largest revenue contributor for Cell Harvesting market companies, driven by strong biologics pipelines, high R&D intensity, and early adoption of cell and gene therapies. Thermo Fisher Scientific Inc., Beckman Coulter Life Sciences, and Terumo Blood and Cell Technologies hold a dominant presence, supported by dense CDMO networks and advanced academic medical centers.

Europe shows robust, innovation-led growth with strong emphasis on single-use technologies, sustainable operations, and regulatory compliance. Sartorius AG, Merck KGaA (MilliporeSigma), and Miltenyi Biotec anchor regional competition. EU funding for advanced therapies and biosimilar production underpins demand for integrated, closed cell harvesting solutions across Germany, France, the UK, and Nordic countries.

Asia Pacific is the fastest-growing region for Cell Harvesting market companies, fueled by expanding biologics capacity in China, South Korea, India, and Singapore. Sartorius AG and GE HealthCare increasingly localize manufacturing and service to compete with emerging regional vendors. Government-backed investments in biosimilars and vaccines create sustained demand for scalable harvest platforms.

Latin America remains a smaller but strategically important growth frontier, with Brazil and Mexico leading adoption of modern bioprocessing. Global Cell Harvesting market companies often pursue distributor-led models and targeted partnerships with regional biopharma and vaccine institutes. Upgrades from legacy equipment to automated, closed systems present a key medium-term opportunity.

The Middle East and Africa region is at an earlier stage but gaining momentum through investments in healthcare infrastructure and vaccine self-sufficiency. Gulf states sponsor new biologics and fill-finish plants, attracting Thermo Fisher Scientific Inc. and Merck KGaA (MilliporeSigma). Over time, these projects will demand higher volumes of reliable cell harvesting and clarification systems.

Across all regions, regulatory expectations around sterility, data integrity, and patient safety are converging upward. Cell Harvesting market companies that offer validated, GMP-ready platforms, strong local service, and digital integration for process analytics are best positioned to win multinational tenders and long-term framework agreements.

Cell Harvesting Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

HemoFlow Systems
Disruptor
USA

Developing microfluidic-based continuous cell harvesting platforms that reduce shear stress and media consumption for small and mid-scale bioreactors.

CytoStream Biotech
Disruptor
Germany

Offers AI-optimized filtration cartridges and disposable harvest manifolds that dynamically adjust flow to maximize cell viability and product yield.

NovaCella Technologies
Disruptor
South Korea

Focuses on closed, modular cell therapy harvesting units designed for hospital-based manufacturing and decentralized production models.

CellFlux Innovations
Disruptor
India

Delivers cost-efficient single-use harvest skids tailored to emerging-market biosimilar manufacturers, emphasizing local service and flexible financing models.

BioHarvest AI
Disruptor
United Kingdom

Provides a cloud-native analytics layer that connects to existing harvest hardware, enabling predictive maintenance and real-time process optimization.

PureSep Analytics
Disruptor
Canada

Combines inline optical sensors with machine learning to monitor harvest quality, targeting integration with leading Cell Harvesting market companies’ platforms.

Cell Harvesting Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Cell Harvesting market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Cell Harvestingmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.